Generic Qulipta Availability
Last updated on May 7, 2025.
Qulipta is a brand name of atogepant, approved by the FDA in the following formulation(s):
QULIPTA (atogepant - tablet;oral)
-
Manufacturer: ABBVIE
Approval date: September 28, 2021
Strength(s): 10MG [RLD], 30MG [RLD], 60MG [RLD]
Is there a generic version of Qulipta available?
No. There is currently no therapeutically equivalent version of Qulipta available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Qulipta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Tablet formulation for CGRP active compounds
Patent 10,117,836
Issued: November 6, 2018
Inventor(s): Johnson Mary Ann & Allain Leonardo Resende & Eickhoff W. Mark & Ikeda Craig B. & Brown Chad D. & Flanagan & Jr. Francis J. & Nofsinger Rebecca & Marota Melanie & Lupton Lisa & Patel Paresh B. & Xi Hanmi & Xu Wei
Assignee(s): Merck Sharp & Dohme Corp.The present invention is directed to compositions comprising an extrudate or solid solution of a compound, or a salt thereof, of Formula I (API): Formula I, wherein “R” is independently H or —F, in a water-soluble polymer matrix which further comprises a disintegration system allowing a tablet made therefrom to rapidly disintegrate in the environment in which the API is to be released.
Patent expiration dates:
- January 30, 2035✓
- January 30, 2035
-
Treatment of migraine
Patent 12,090,148
Issued: September 17, 2024
Inventor(s): Trugman; Joel et al.
Assignee(s): Allergan Pharmaceuticals International Limited (Dublin, IE)The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.
Patent expiration dates:
- July 29, 2041✓
- July 29, 2041
-
Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent 8,754,096
Issued: June 17, 2014
Inventor(s): Bell Ian M. & Fraley Mark E. & Gallicchio Steven N. & Ginnetti Anthony & Mitchell Helen J. & Paone Daniel V. & Staas Donnette D. & Stevenson Heather E. & Wang Cheng & Zartman C. Blair
Assignee(s): Merck Sharp & Dohme Corp.The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Patent expiration dates:
- July 19, 2032✓✓✓
- July 19, 2032
-
Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent 9,499,545
Issued: November 22, 2016
Inventor(s): Bell Ian M. & Fraley Mark E. & Gallicchio Steven N. & Ginnetti Anthony & Mitchell Helen J. & Paone Daniel V. & Staas Donnette D. & Wang Cheng & Zartman C. Blair
Assignee(s): Merck Sharp & Dohme Corp.The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Patent expiration dates:
- November 10, 2031✓✓✓
- November 10, 2031
-
Process for making CGRP receptor antagonists
Patent 9,850,246
Issued: December 26, 2017
Inventor(s): Chen Frank & Molinaro Carmela & Wuelfing W. Peter & Yasuda Nobuyoshi & Yin Jianguo & Zhong Yong-Li & Lynch Joseph & Andreani Teresa
Assignee(s): MERCK SHARP & DOHME CORP.The invention encompasses a novel process for making piperidinone carboxamide indane and azainane derivatives, which are CGRP receptor antagonists useful for the treatment of migraine.
Patent expiration dates:
- March 13, 2033✓
- March 13, 2033
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 17, 2026 - PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS
- September 28, 2026 - NEW CHEMICAL ENTITY
More about Qulipta (atogepant)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (177)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Support group
- FDA approval history
- Drug class: CGRP inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
